Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
34 hedge funds and large institutions have $3.76M invested in Checkpoint Therapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 3 reducing their positions, and 11 closing their positions.
467% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 3
91% more call options, than puts
Call options by funds: $300K | Put options by funds: $157K
1.72% more ownership
Funds ownership: 22.2% → 23.92% (+1.7%)
15% less funds holding
Funds holding: 40 → 34 (-6)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
84% less capital invested
Capital invested by funds: $23.4M → $3.76M (-$19.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$1.1M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$732K |
| 3 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$413K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$151K |
| 5 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$82.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TwinBeech Capital
Purchase,
New York
|
-$14.3M |
| 2 |
AC
Armistice Capital
New York
|
-$3.54M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1,000K |
| 4 |
PAS
Park Avenue Securities
New York
|
-$238K |
| 5 |
Millennium Management
New York
|
-$188K |
CKPT Hedge Fund Activity: Q1 2023 in Review
34 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q1 2023, worth a combined $3.76M — down 84% from $23.4M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CKPT and 7 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 17 added.
The largest buyer was Cowen and Company, opening a new position worth an estimated $1.1M. The largest seller was TwinBeech Capital, exiting entirely with an estimated $14.3M sold.
- 34 institutional investors held Checkpoint Therapeutics (CKPT) as of Q1 2023, down from 40 in Q4 2022.
- Funds reported $3.76M of Checkpoint Therapeutics stock for Q1 2023, down 84% quarter-over-quarter.
- 7 funds opened new Checkpoint Therapeutics positions in Q1 2023 and 11 closed out, a net change of -4 holders.
- The largest Checkpoint Therapeutics buyer in Q1 2023 was Cowen and Company, an estimated $1.1M added.
- The largest Checkpoint Therapeutics seller in Q1 2023 was TwinBeech Capital, an estimated $14.3M sold.
Based on aggregated 13F filings for Q1 2023.